Computational prediction of interactions between Paxlovid and prescription drugs.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36913586.
- Also identified by DOI 10.1073/pnas.2221857120 and PMC identifier 10041137.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Pfizer's Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients with underlying medical conditions, such as hypertension and diabetes, who have likely been taking other drugs. Here, we use deep learning to predict potential drug-drug interactions between Paxlovid components (nirmatrelvir and ritonavir) and 2,248 prescription drugs for treating various diseases.
Medical subject headings
- Prescription Drugs
- COVID-19